Injectable drug¶ | 39 (90.7) | 6.2 (5.2–7.4) months | 22 (56.4) | |
Linezolid | 38 (88.4) | 9.6 (5.6–14.8) months | 26 (68.4) | |
Fluoroquinolone+ | 40 (93.0) | 23.3 (15.8–24.8) months | 10 (25.0) | |
Clofazimine | 23 (53.5) | 12.3 (5.6–21.1) months | 2 (8.7) | |
Bedaquiline§ | 5 (11.6) | 5.9 (4.5–15.6) months | 0 (0) | |
Duration of effective MDR-TB treatment | | 23.8 (17.8–25.8) months | | |
Adverse event for any drug | | | 38 (88.4) | |
Number of drugs in intensive phase | | | | 6 (5–6) |
Number of drugs in continuation phase | | | | 4 (4–5) |
Duration of hospitalisation | | 50 (38–108) days | | |
Cases with all MDR-TB medicines paused | 14 (32.6) | | | |
Duration of pauses for cases with pauses in medication | | 9.0 (5.5–14.0) days | | |
DOT used | 42 (97.7) | | | |